Price
No data yet.
Social Signal Score
Revenue
$0.00-100.00%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Carsten Brunn
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 75
- Beta
- 0.62
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -4.50
Financials
Revenue
$0.00-100.0%Net Income
$13.72MEBITDA
$17.42MFree Cash Flow
$-20.90MEPS (diluted)
$0.46Shares Outstanding (diluted)
29.86M+5836.6%Operating Expenses
$29.16MCash & Debt
$147.61MRevenue by Segment (annual)
$2.80MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $2.80M | $-130.30M | $-5.02 |
| 2024 | $38.91M | $-77.42M | $-3.29 |
| 2023 | $26.00M | $-219.71M | $-49.76 |
| 2022 | $110.78M | $35.38M | $7.33 |
| 2021 | $85.08M | $-25.69M | $-6.74 |
| 2020 | $16.60M | $-68.88M | $-20.42 |
| 2019 | $6.68M | $-55.35M | $-36.46 |
| 2018 | $903.0K | $-65.34M | $-87.55 |
| 2017 | $207.0K | $-65.32M | $-95.94 |
| 2016 | $8.08M | $-36.21M | $-103.52 |
| 2015 | $6.01M | $-25.17M | $-75.79 |
| 2014 | $3.04M | $-12.88M | $-38.17 |
Valuation
RNAChas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
80+0.00%Social Signal Score
Mentions (2)
- Newsglobenewswire.com·1d ago·Negative
Cartesian Therapeutics Announces New Employment Inducement Grants FREDERICK, Md., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of inducement awards to three new employees.
View source ↗ - Newsglobenewswire.com·6d ago·Negative
Cartesian Therapeutics to Participate in Upcoming Investor Conferences FREDERICK, Md., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced that its management expects to participate in the following investor conferences in September:
View source ↗
Earnings
Thu, Nov 5(in 8 weeks)
Consensus estimate $-1.02 per share
Typical surprise -11.5% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$0.46 vs $-0.88beat
- Thu, Apr 30$-1.46 vs $-0.84miss
- Mon, Mar 9$-1.38 vs $-0.82miss
- Thu, Nov 6$-1.38 vs $-0.81miss
- Thu, Aug 7$0.50 vs $-0.76beat
- Thu, May 8$-0.68 vs $-0.61miss
Estimates and results for RNAC via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by RNAC officers and directors.
- Bought
- $3.5m
- Sold
- $869k
17 trades
15 trades
- Brunn Carstensold
- Miljkovic Milossold
- Davis Blainesold
- Barabe Timothy Cbought
- Springer Timothy Abought
- Springer Timothy Abought
- Springer Timothy Abought
- Springer Timothy Abought
68 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.